MedReleaf (TSX:LEAF) announced it became the first medical cannabis producer to receive an International Council on Harmonization certification for Good Manufacturing Practices for Active Pharmaceutical Ingredients.

As quoted in the press release:

MedReleaf’s wide-ranging ICH-GMP compliance certification covers the Research and Development, Production, Distribution, Processing, Selling, and Destruction of medical cannabis for its Markham facility.

Although there are a number of different GMP certifying bodies, the ICH-GMP is the globally accepted standard for the pharmaceutical industry recognized by regulatory authorities around the world including Canada, the United States, EU, Japan, Singapore and Australia.

MedReleaf’s ICH-GMP certification will support the Company’s international growth and commitment to maintaining its position as the Medical Grade Standard in a number of ways, including:

Providing the Company with a global manufacturing practice and platform that complies with GMP requirements around the world.

Facilitating the sale of MedReleaf products to any global market allowing the import of medical cannabis.

Accelerating MedReleaf’s partnerships with pharmaceutical and biotech companies as the only ICH-GMP certified producer of medical cannabis that can be used in late-stage clinical trials around the world.